A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

JCO Precis Oncol. 2022 Nov:6:e2200006. doi: 10.1200/PO.22.00006.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Designed Ankyrin Repeat Proteins
  • Female
  • Humans
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / therapeutic use

Substances

  • ERBB2 protein, human
  • Trastuzumab
  • pertuzumab
  • Designed Ankyrin Repeat Proteins
  • Receptor, ErbB-2
  • Antineoplastic Agents